AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 173 filers reported holding AXSOME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $475 | +6.5% | 6,800 | +9.7% | 0.00% | +50.0% |
| Q2 2023 | $446 | +29.3% | 6,200 | +10.7% | 0.00% | 0.0% |
| Q1 2023 | $345 | +6.5% | 5,600 | +33.3% | 0.00% | 0.0% |
| Q4 2022 | $324 | -99.9% | 4,200 | -35.4% | 0.00% | 0.0% |
| Q3 2022 | $290,000 | +16.5% | 6,500 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $249,000 | -19.7% | 6,500 | -13.3% | 0.00% | 0.0% |
| Q1 2022 | $310,000 | +9.5% | 7,500 | 0.0% | 0.00% | +100.0% |
| Q4 2021 | $283,000 | +38.7% | 7,500 | +21.0% | 0.00% | 0.0% |
| Q3 2021 | $204,000 | -51.2% | 6,200 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $418,000 | +22.9% | 6,200 | +3.3% | 0.00% | 0.0% |
| Q1 2021 | $340,000 | -30.5% | 6,000 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $489,000 | +14.3% | 6,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $428,000 | -56.7% | 6,000 | -50.0% | 0.00% | -25.0% |
| Q2 2020 | $988,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |